Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors
Nelson, Blessie Elizabeth , Jankú, Filip , Fu, Siqing , Dumbrava, Ecaterina E. , Hong, David S. , Karp, Daniel D. , Naing, Aung , Tsimberidou, Apostolia M. , Murthy, Ravi , Sheth, Rahul A. , Amaria, Rodabe N. , Carapanceanu, Nicoleta, Singh, Mahendra Pal , Carapanceanu, Valentin, Pezeshki, Abdulmohammad , Leontovich, Alexey A. , Kreider, Brent L. , Tung, David, Varterasian, Mary , Khazaie, Khashayarsha , Piha‐Paul, Sarina A. , Rodon, Jordi , Tsimberidou, Apostolia Maria , Murthy, Ravi , Sheth, Rahul A , Amaria, Rodabe N , Conley, Anthony P , Damodaran, Senthil , Raghav, Kanwal P S , Carapanceanu, Nicoleta , Singh, Mahendra Pal , Carapanceanu, Valentin , Pezeshki, Abdulmohammad , Kreider, Brent , Tung, David , Varterasian, Mary , Khazaie, Khashayarsha , Piha-Paul, Sarina A , Hong, David S , Conley, Anthony P. , Raghav, Kanwal

Clinical Cancer Research | July 11, 2025 | Volume: 31 | Issue: 18 | Pages: 3864-3875

10.1158/1078-0432.ccr-24-3952 | PMID 40643985 Get It

Abstract Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi-NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi-NT injection (day 8) across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 104C.novyi-NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi-NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Outcomes of Acute Myocardial Infarction in Patients With vs. Without Systemic Lupus Erythematosus
Jabbar, Ali Bin Abdul, Aboeata, Ahmed, Abdul Jabbar, Ali Bin , Ismayl, Mahmoud , Walters, Ryan W. , Goldsweig, Andrew M. , Aronow, Herbert D.

Graduate Medical Education Research Journal | July 11, 2025 | Volume: 7 | Issue: 1 | Pages: 33-34

10.32873/unmc.dc.gmerj.7.1.039 Get It

Ventricular Tachycardia Ablation in Patients with Valvular Heart Disease
Khalil, Fouad, Siontis, Konstantinos C. , Sugrue, Alan , Killu, Ammar M. , Khalil, Fouad, Toya, Takumi , Kowlgi, Gurukripa N. , Kapa, Suraj

Graduate Medical Education Research Journal | July 11, 2025 | Volume: 7 | Issue: 1 | Pages: 19-20

10.32873/unmc.dc.gmerj.7.1.014 Get It

The Challenges of Diagnosing, Managing, and Preventing Pediatric Delirium
Almeida, Juliana Patrícia Chaves de, Kawai, Yu , Prata‐Barbosa, Arnaldo , Kawai, Yu , Castro, Roberta Esteves Vieira de

Children | July 11, 2025 | Volume: 12 | Issue: 7 | Pages: 918

10.3390/children12070918 | PMID 40723111 Get It

Pediatric delirium (PD) is an acute neuropsychiatric syndrome marked by fluctuating disturbances in attention and cognition, frequently observed in pediatric intensive care units (PICUs) and associated with increased morbidity, mortality, and long-term cognitive impairment. Despite its clinical significance, PD remains underdiagnosed due to challenges inherent in assessing consciousness and cognition in children at varying developmental stages. Several bedside tools have been developed and validated in recent years, including the Cornell Assessment of Pediatric Delirium (CAPD), PreSchool Confusion Assessment Method for the Intensive Care Unit (psCAM-ICU); Pediatric Confusion Assessment Method for the Intensive Care Unit (pCAM-ICU), and Sophia Observation Withdrawal Symptoms—Pediatric Delirium Scale (SOS-PD), enhancing early recognition and management of PD in critically ill children. This narrative review explores the historical background, epidemiology, risk factors, pathophysiology, clinical subtypes, diagnostic tools, and current prevention and treatment strategies for PD from newborns to 21 years old. The screening tools available and the integration of non-pharmacological interventions, such as environmental modifications and family-centered care, as well as cautious and selective pharmacological management, are emphasized in this review. Early identification and targeted interventions are essential to mitigate the adverse outcomes associated with PD.
Association of right ventricular dysfunction with blood volume expansion to outcomes in chronic left-sided heart failure
Miller, Wayne L. , Скидан, В. И. , Pislaru, Sorin V. , Skidan, Viktoria I , Sabbah, Michael S. , Miller, Wayne L. , Nkomo, Vuyisile T.

American Journal of Physiology-Heart and Circulatory Physiology | July 11, 2025 | Volume: 329 | Issue: 2 | Pages: H515-H520

10.1152/ajpheart.00415.2025 | PMID 40643444 Get It

This analysis provides a novel assessment of the relationship between the severity of right ventricular dysfunction (RVD) and blood volume expansion (BVE) on clinical outcomes in patients with chronic left-sided heart failure. Findings demonstrate that despite the high prevalence of moderate or greater RVD, persistent BVE was associated with better 1-year event-free survival relative to normal BV. Hypothesis-generating, this suggests that BVE may provide an adaptive response compensating in part for the impact of RVD in chronic HF.
Erythema Nodosum Leprosum in a Patient with Borderline Lepromatous Leprosy: A Case Report
Chiriboga, Guido , Guo, Qianyu , Zuberi, Eric , Powers, H. R. , Prada, Libardo Rueda , Powers, Harry R , Rueda Prada, Libardo , Yang, Vivienne , Zuberi, Eric C.

Infectious Disease Reports | July 11, 2025 | Volume: 17 | Issue: 4 | Pages: 83

10.3390/idr17040083 | PMID 40700329 Get It

Background: Leprosy, caused by Mycobacterium leprae, presents on a spectrum ranging from tuberculoid to lepromatous disease. Borderline lepromatous leprosy represents an unstable immunological state that predisposes patients to immune-mediated reactions, including erythema nodosum leprosum (ENL), a severe inflammatory complication. Case Presentation: We report a case of a 62-year-old female with borderline lepromatous leprosy who presented with recurrent facial cellulitis and later developed disseminated ENL. She was initially diagnosed following a series of facial infections and confirmatory skin biopsy. Months later, she developed systemic inflammatory lesions consistent with ENL, requiring hospitalization. She was treated with high-dose corticosteroids for ENL and methotrexate to treat type 1 reaction and continued multidrug therapy (MDT) with minocycline, rifampin, and clarithromycin for leprosy, which led to significant clinical improvement. Conclusion: This case highlights the diagnostic challenges of leprosy in the United States and the importance of recognizing ENL as a severe immunologic complication requiring prompt intervention. A multidisciplinary approach is essential for optimal patient outcomes.
How much energy does overcoming air resistance cost at 4-min-mile pace?
Silva, Edson Soares da , Hoogkamer, Wouter , Kipp, Shalaya , Kram, Rodger , da Silva, Edson Soares , Kipp, Shalaya

Journal of Applied Physiology | July 11, 2025 | Volume: 139 | Issue: 1 | Pages: 260-261

10.1152/japplphysiol.00456.2025 | PMID 40643402 Get It

An anerobic boost to a sub-4-min mile
Kipp, Shalaya , Ramsook, Andrew H. , Joyner, Michael J. , Joyner, Michael J , Ramsook, Andrew H , Kipp, Shalaya

Journal of Applied Physiology | July 11, 2025 | Volume: 139 | Issue: 1 | Pages: 262-262

10.1152/japplphysiol.00452.2025 | PMID 40643409 Get It

Update on North American tick-borne diseases and how to diagnose them
Rodino, Kyle G. , Theel, Elitza S. , Pritt, Bobbi S. , Pritt, Bobbi S

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00807-23 | PMID 40643260 Get It

ABSTRACT Recent decades have seen a rise in the incidence of tick-borne diseases in the US, along with an increased number of pathogens transmitted by ticks, and geographic expansion of tick populations. A variety of laboratory testing methodologies are available for the diagnosis of tick-borne diseases, including serology, microscopy, and molecular-based methods. The preferred approach varies by the specific disease, locally available test options, and the stage of illness at patient presentation. This mini-review focuses on updates in our understanding of the epidemiology of tick-borne diseases in the US and advances in the field of laboratory diagnostics.
Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization
Fabre, Valeria , Hsu, Yea‐Jen , Carroll, Karen C. , Salinas, Alejandra , Abbo, Lilian M. , Bower, Chris , Berry, J. Michael, Degnan, Kathleen, Dhaubhadel, Pragya, Dress, Marci, Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glasser, Laurel J., Johnson, J. Kristie, Karaba, Sara M. , Kubischta, Alyssa, Landrum, B. Mark, Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Qasba, Sonia, Rittmann, Barry , Robinson, Evan D. , Rosa, Rossana , Salinas, Jorge , Shah, Aditya , Schrank, Gregory M. , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Virk, Zunaira, Cosgrove, Sara E. , Abbo, Lilian M , Karaba, Sara M , Fabre, Valeria , Milstone, Aaron M. , Berry, Jennifer, Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Glasser, Laurel J., Howard‐Anderson, Jessica , Kim, Justin , Mathers, Amy J. , Moehring, Rebekah W. , O’Horo, John C. , Rodriguez‐Nava, Guillermo , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van , Gadala, Avinash

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00530-25 | PMID 40643261 Get It

ABSTRACT Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship. IMPORTANCE Blood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.